A Randomized, Double-blind, Multicenter Trial Comparing Efficacy and Safety of Imipenem/Cilastatin/Relebactam Versus Piperacillin/Tazobactam in Adults With Hospital-acquired or Ventilator-associated Bacterial Pneumonia (RESTORE-IMI 2 Study)
Current Language EN
English English Türkçe Türkçe Español Español Português Português Pусский Pусский Filipino Filipino Tiếng Việt Tiếng Việt हिन्दी हिन्दी العربية العربية বাংলা বাংলা Deutsch Deutsch 中文 中文

A Randomized, Double-blind, Multicenter Trial Comparing Efficacy and Safety of Imipenem/Cilastatin/Relebactam Versus Piperacillin/Tazobactam in Adults With Hospital-acquired or Ventilator-associated Bacterial Pneumonia (RESTORE-IMI 2 Study)

Titov, Ivan;Wunderink, Richard G;Roquilly, Antoine;Rodríguez Gonzalez, Daniel;David-Wang, Aileen;Boucher, Helen W;Kaye, Keith S;Losada, Maria C;Du, Jiejun;Tipping, Robert;Rizk, Matthew L;Patel, Munjal;Brown, Michelle L;Young, Katherine;Kartsonis, Nicholas A;Butterton, Joan R;Paschke, Amanda;Chen, Luke F;
clinical infectious diseases pp. -
165
ivanclinicala

Abstract

Imipenem/cilastatin/relebactam was noninferior to piperacillin/tazobactam for treating hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VAB

Keywords

Access

URL:
https://doi.org/10.1093/cid/ciaa803

Citation

ID: 112758
Ref Key: ivanclinicala
Use this key to autocite in SciMatic or Thesis Manager

References

References

No Bibliography

Blockchain Verification

Account:
NFT Contract Address:
0x95644003c57E6F55A65596E3D9Eac6813e3566dA
Article ID:
112758
Unique Identifier:
Network:
Scimatic Chain (ID: 481)
Blockchain Readiness Checklist
Authors
Abstract
Journal Name
Year
Title
4/5
Blockchain Upload Locked

Complete all 5 checklist items to tokenize your article

Gas fees required in SCI Coins
Buy SCI

Saymatik Web3.0 Wallet

Google Play
App Store